Sajazir

Drug Overview

In the highly specialized field of hematology and immunology, treating sudden and severe swelling episodes requires fast-acting and precise medical intervention. Sajazir is an advanced medication classified as a Bradykinin B2 Receptor Antagonist. It acts as a Targeted Therapy for patients suffering from a rare genetic blood and immune system disorder known as Hereditary Angioedema (HAE).

For patients living with HAE, sudden attacks of swelling can be painful, debilitating, and in some cases, life-threatening. Sajazir offers rapid relief by directly blocking the specific molecule in the blood responsible for this severe swelling.

• Generic Name: icatibant
• US Brand Names: Sajazir (also available as Firazyr)
• Route of Administration: Subcutaneous (SC) injection (injected into the fatty tissue of the abdomen)
• FDA Approval Status: FDA-approved for the treatment of acute attacks of Hereditary Angioedema in adults 18 years of age and older.

What Is It and How Does It Work? (Mechanism of Action)

Without a functioning C1-esterase inhibitor, a specific chain reaction in the blood plasma (the contact activation system, which is closely tied to the intrinsic coagulation cascade) goes into overdrive. This overactivity leads to the massive overproduction of a small peptide called bradykinin.

Bradykinin is a powerful vasodilator. At the molecular and hematological level, it binds to Bradykinin B2 receptors located on the walls of blood vessels. When bradykinin attaches to these receptors, it forces the blood vessels to widen and become “leaky.” Fluid rushes out of the bloodstream and into the surrounding tissues, causing the massive, painful swelling characteristic of an HAE attack.

Sajazir operates as a potent Targeted Therapy. It is a synthetic peptide that looks very similar to bradykinin, but it does not cause swelling. Instead, it competes with bradykinin and firmly binds to the Bradykinin B2 receptors, blocking the real bradykinin from attaching. By effectively sealing off these receptors, Sajazir stops the blood vessels from leaking fluid, thereby halting the progression of the swelling and allowing the tissues to return to normal.

FDA-Approved Clinical Indications

Primary Indication

Within the hematology and clinical immunology category, the specific use for Sajazir is the treatment of acute attacks of Hereditary Angioedema (HAE) in adults. This means the medication is used “on-demand” to stop an attack once it has already started. It is highly effective in treating swelling attacks located in the abdomen, face, extremities (hands and feet), and the larynx (throat).

Other Approved & Off-Label Uses

While officially approved for acute HAE attacks, medical professionals sometimes utilize this Targeted Therapy in other emergency settings:

• Treatment of Angiotensin-Converting Enzyme (ACE) inhibitor-induced angioedema (Off-label use for severe swelling caused by specific blood pressure medications).
• Acquired Angioedema (Off-label use for non-hereditary forms of C1-inhibitor deficiency).

Dosage and Administration Protocols

Sajazir is supplied as a single-use, prefilled syringe. It is designed to be self-administered by the patient or a caregiver once they have been trained by a healthcare professional.

Important Adjustments:

• Renal/Hepatic Insufficiency: No dose adjustment is required for patients with kidney or liver impairment. The drug is cleared from the body safely regardless of mild to moderate organ dysfunction.
• Elderly Patients: No specific dose adjustments are required based on age, though general caution is advised.
• Weight-based Dosing: In the US, the standard adult dose is a flat 30 mg and does not require weight-based adjustments.

Clinical Efficacy and Research Results

Clinical study data from 2020-2026 continues to support the robust efficacy of icatibant therapies like Sajazir. In the foundational FAST clinical trials and subsequent real-world registry data, patients treating an acute HAE attack with this medication experienced a median time to 50 percent symptom relief of approximately 2.0 hours, compared to nearly 20 hours for patients who did not receive the drug.

Recent observational studies indicate that early administration (injecting the medication as soon as the patient feels the initial signs of an attack) significantly reduces the overall duration and severity of the episode. This rapid response is particularly crucial for laryngeal (throat) attacks, where prompt administration dramatically reduces the risk of asphyxiation and the need for emergency airway intubation.

Safety Profile and Side Effects

Black Box Warning

There is no Black Box Warning for Sajazir. It is generally considered highly safe for its approved indications.

Common side effects (>10%)

• Injection Site Reactions: This is the most common side effect, occurring in nearly all patients (up to 97 percent). It includes redness, bruising, swelling, warmth, burning, or itching specifically at the injection site. This reaction is usually mild to moderate and resolves on its own within a few hours.
• Fever
• Transaminase (liver enzyme) increases
• Dizziness
• Nausea

Serious adverse events

• Hypersensitivity: While rare, severe allergic reactions to the medication’s ingredients are possible.
• Laryngeal Attack Progression: Although Sajazir treats laryngeal attacks, patients must remain vigilant; if the swelling in the throat does not improve, it can lead to airway obstruction.

Management Strategies

For injection site reactions, applying a cold compress or ice pack to the area after administering the injection can help soothe burning and reduce redness. If a patient experiences a laryngeal (throat) attack, they must inject Sajazir immediately and then proceed to the nearest emergency room for medical observation, even if they feel the medication is working.

Research Areas

In the advancing field of hematology and HAE management, current research is exploring the expansion of Bradykinin B2 Receptor Antagonists for pediatric populations, as currently, Sajazir is only approved in the US for adults. Furthermore, while Sajazir is an on-demand treatment, researchers are investigating novel oral bradykinin inhibitors and gene-editing technologies that may one day prevent the bradykinin surge from happening altogether, potentially offering a permanent cure for HAE.

Disclaimer: The research mentioned regarding the use of marstacimab in patients with inhibitors and in pediatric populations under 12 is an active area of investigation in 2026. While the “rebalancing” concept is theoretically ideal for inhibitor patients, specific FDA approval for these groups is distinct from the current approval for non-inhibitor patients.

Patient Management and Practical Recommendations

Pre-treatment Tests

• C1-Esterase Inhibitor Function Test: To confirm the diagnosis of Hereditary Angioedema.
• C4 Complement Levels: A standard blood test that is typically low in patients with HAE, used during initial diagnosis.
• No routine pre-dose testing is required immediately before administering Sajazir during an attack.

Precautions during treatment

• Laryngeal Attacks: Any swelling involving the face, mouth, tongue, or throat requires immediate administration of Sajazir followed by emergency medical care to monitor the airway.
• Cardiac Precautions: Patients with severe ischemic heart disease should be monitored if using Sajazir, as sudden changes in blood vessel dilation could theoretically impact heart function.

“Do’s and Don’ts” List

• DO carry your Sajazir prefilled syringe with you at all times; HAE attacks are unpredictable.
• DO ensure a family member or caregiver is trained on how to administer the injection in case you are unable to do it yourself.
• DO rotate your injection sites across different areas of your abdomen, keeping at least 2 inches away from your belly button.
• DON’T freeze the medication; store it at a controlled room temperature (between 36 degrees and 77 degrees Fahrenheit).
• DON’T inject the medication into skin that is bruised, tender, red, or hard.
• DON’T hesitate to use the medication at the first sign of an attack; early treatment yields the best results.

Legal Disclaimer

For informational purposes only, does not replace professional medical advice from a qualified healthcare provider. Hereditary Angioedema is a complex and potentially life-threatening condition. Always consult your hematologist, immunologist, or primary care physician for a proper diagnosis, a personalized emergency action plan, and guidance on how to safely self-administer injectable medications.